{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T05:16:08Z","timestamp":1784438168850,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJID Regions"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijregi.2025.100816","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:18:41Z","timestamp":1764404321000},"page":"100816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Identification of NS5B resistance-associated mutations in hepatitis C virus circulating in treatment-na\u00efve Cameroonian patients"],"prefix":"10.1016","volume":"18","author":[{"given":"Aristide","family":"Mounchili-Njifon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdou Fatawou","family":"Modiyinji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pretty Rosereine","family":"Mbouyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chavely Gwladys","family":"Monamele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moise Henri","family":"Moumbeket-Yifomnjou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipe Herman Njitoyap","family":"Mfombouot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele Liliane","family":"Machuetum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal Ibrahim","family":"Toueyem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Frederic","family":"Lissock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Alain","family":"Tagnouokam-Ngoupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Paul Assam","family":"Assam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Njouom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijregi.2025.100816_bib0001","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/HMER.S470344","article-title":"Advancing hepatitis C elimination in Africa: insights from Egypt","volume":"16","author":"Salomon","year":"2024","journal-title":"Hepat Med"},{"key":"10.1016\/j.ijregi.2025.100816_bib0002","unstructured":"World Health Organization. Hepatitis C, fact sheet, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c; 2024 [accessed 29 April 2024]."},{"key":"10.1016\/j.ijregi.2025.100816_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV] - A web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents","volume":"11","author":"Kalaghatgi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijregi.2025.100816_bib0004","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","article-title":"New horizons in hepatitis C antiviral therapy with direct-acting antivirals","volume":"58","author":"Aghemo","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ijregi.2025.100816_bib0005","article-title":"Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic hepatitis C","volume":"16","author":"Ahmed","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ijregi.2025.100816_bib0006","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/medicina54050080","article-title":"Current status of direct acting antiviral agents against hepatitis C virus infection in Pakistan","volume":"54","author":"Khaliq","year":"2018","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.ijregi.2025.100816_bib0007","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijregi.2025.100816_bib0008","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijregi.2025.100816_bib0009","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/13543784.2018.1420780","article-title":"NS5B polymerase inhibitors in phase II clinical trials for HCV infection","volume":"27","author":"Borgia","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijregi.2025.100816_bib0010","doi-asserted-by":"crossref","first-page":"ofz076","DOI":"10.1093\/ofid\/ofz076","article-title":"Identification of 19 novel hepatitis C virus subtypes-further expanding HCV classification","volume":"6","author":"Hedskog","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijregi.2025.100816_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijregi.2025.100816_bib0012","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.coviro.2014.07.010","article-title":"Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevance","volume":"8","author":"G\u00f6tte","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.ijregi.2025.100816_bib0013","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4685-gmb-2018-0237","article-title":"Resistance mutations of NS3 and NS5b in treatment-na\u00efve patients infected with hepatitis C virus in Santa Catarina and Rio Grande do Sul states, Brazil","volume":"43","author":"Andrade","year":"2020","journal-title":"Genet Mol Biol"},{"key":"10.1016\/j.ijregi.2025.100816_bib0014","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000528178","article-title":"Hepatitis C virus Genotype 5 variability in treatment-na\u00efve patients in South Africa","volume":"66","author":"Maunye","year":"2023","journal-title":"Intervirology"},{"key":"10.1016\/j.ijregi.2025.100816_bib0015","article-title":"Prevalence of NS5B resistance mutations in hepatitis C virus (HCV) treatment na\u00efve South Africans","author":"Gededzha","year":"2017","journal-title":"Hepatology Forum"},{"key":"10.1016\/j.ijregi.2025.100816_bib0016","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.55522\/jmpas.V12I2.4763","article-title":"C316N Polymorphism associated with resistance to HCV polymerase NS5B in treatment-na\u00efve patient with chronic hepatitis C","volume":"12","author":"Raiss","year":"2023","journal-title":"J Med Pharm Allied Sci"},{"key":"10.1016\/j.ijregi.2025.100816_bib0017","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/IDR.S353605","article-title":"Identification of NS5B resistance-associated mutations in hepatitis C virus circulating in treatment na\u00efve Vietnamese patients","volume":"15","author":"Nguyen","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijregi.2025.100816_bib0018","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1743-422X-10-355","article-title":"Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-na\u00efve patients","volume":"10","author":"Paolucci","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.ijregi.2025.100816_bib0019","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/diagnostics12051054","article-title":"Distribution of primary resistance mutations in Saint Petersburg in patients with chronic hepatitis C","volume":"12","author":"Valutite","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ijregi.2025.100816_bib0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00705-017-3640-6","article-title":"Prevalence of NS5B resistance-associated variants in treatment-na\u00efve Asian patients with chronic hepatitis C","volume":"163","author":"Yang","year":"2018","journal-title":"Arch Virol"},{"key":"10.1016\/j.ijregi.2025.100816_bib0021","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1111\/jam.15754","article-title":"Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients","volume":"133","author":"Younas","year":"2022","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.ijregi.2025.100816_bib0022","doi-asserted-by":"crossref","first-page":"97","DOI":"10.21055\/0370-1069-2020-3-97-105","article-title":"Primary HCV drug resistance mutations in patients with newly diagnosed HIV infection","volume":"0","author":"Ostankova","year":"2020","journal-title":"Problemy Osobo Opasnykh Infektsii"},{"key":"10.1016\/j.ijregi.2025.100816_bib0023","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/tmi.13450","article-title":"Achieving a high cure rate with direct-acting antivirals for chronic hepatitis C virus infection in Cameroon: a multi-clinic demonstration project","volume":"25","author":"Coyer","year":"2020","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.ijregi.2025.100816_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/BMRJ\/2016\/28823","article-title":"Hepatitis C virus genetic diversity and drug mutational analysis in Cameroon: 1992 to 2013","volume":"17","author":"Torimiro","year":"2016","journal-title":"Br Microbiol Res J"},{"key":"10.1016\/j.ijregi.2025.100816_bib0025","doi-asserted-by":"crossref","first-page":"e40959","DOI":"10.5812\/hepatmon.guideline","article-title":"Recommendations for the clinical management of hepatitis C in Iran: a consensus-based national guideline","volume":"16","author":"Alavian","year":"2016","journal-title":"Hepat Mon"},{"key":"10.1016\/j.ijregi.2025.100816_bib0026","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0166-0934(03)00070-3","article-title":"Determining hepatitis C genotype by analyzing the sequence of the NS5b region","volume":"109","author":"Sandres-Saun\u00e9","year":"2003","journal-title":"J Virol Methods"},{"key":"10.1016\/j.ijregi.2025.100816_bib0027","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijregi.2025.100816_bib0028","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/pathogens13040339","article-title":"Chronic hepatitis C virus infection, extrahepatic disease and the impact of new direct-acting antivirals","volume":"13","author":"M\u00e9ndez-S\u00e1nchez","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.ijregi.2025.100816_bib0029","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijregi.2025.100816_bib0030","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1002\/jmv.25536","article-title":"Hepatitis C virus genotype 1 infection: prevalence of NS5A and NS5B resistance-associated substitutions in na\u00efve patients from Argentina","volume":"91","author":"Mart\u00ednez","year":"2019","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijregi.2025.100816_bib0031","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.21608\/nrmj.2024.264515.1425","article-title":"Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with hepatitis C virus genotype 4a","volume":"8","author":"Mohamed","year":"2024","journal-title":"Novel Res Microbiol J"},{"key":"10.1016\/j.ijregi.2025.100816_bib0032","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/cld.768","article-title":"Novel NS5B resistance-associated substitution emerges under failing Sofosbuvir\/Ledipasvir therapy","volume":"13","author":"Catalli","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.ijregi.2025.100816_bib0033","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep4.1060","article-title":"The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment","volume":"1","author":"Gane","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ijregi.2025.100816_bib0034","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jcv.2013.09.022","article-title":"No detection of the NS5B S282T mutation in treatment-na\u00efve genotype 1 HCV\/HIV-1 coinfected patients using deep sequencing","volume":"58","author":"Franco","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ijregi.2025.100816_bib0035","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2991\/jegh.k.200117.002","article-title":"Efficacy of DAAs in the treatment of chronic HCV: real-world data from the private health-care sector of the Kingdom of Saudi Arabia","volume":"10","author":"Hashim","year":"2020","journal-title":"J Epidemiol Glob Health"},{"key":"10.1016\/j.ijregi.2025.100816_bib0036","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1590\/S0074-02762011000800011","article-title":"Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients","volume":"106","author":"Castilho","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.ijregi.2025.100816_bib0037","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"Tong","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijregi.2025.100816_bib0038","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["IJID Regions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772707625002504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772707625002504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:43:41Z","timestamp":1773913421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772707625002504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["S2772707625002504"],"URL":"https:\/\/doi.org\/10.1016\/j.ijregi.2025.100816","relation":{},"ISSN":["2772-7076"],"issn-type":[{"value":"2772-7076","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of NS5B resistance-associated mutations in hepatitis C virus circulating in treatment-na\u00efve Cameroonian patients","name":"articletitle","label":"Article Title"},{"value":"IJID Regions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijregi.2025.100816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"100816"}}